News

Sanderson McLeod looks back at the most robust year in life science investment and recruiting.

NEWS PROVIDED BY Paul Sanderson    January 14, 2019

2018 saw a record amount of private investment in healthcare stocks. We also witnessed multi-billion dollar acquisitions with both BMS and Lilly buying Celgene and Loxo Oncology days before the JP Morgan Healthcare Conference. 

Our firm was fortunate to work with some of the best and brightest innovators in the market. Clients included Turnstone Biologics,  Logic Biotherapeutics,  Annexon Biosciences,  Endotronix,  IGM biosciences,  Onconova, Shockwave MedicalViracta, and Zymeworks.

Hires were in numerous functional categories including Chief Medical Officer for Onconova,  and SVP of Sales and Marketing for Endotronix.

For 2019 we see a number of new modalities gaining traction. With Spark Therapeutics gaining approval  for the first gene therapy in the US and EU, and Avexis signing a 8.7 billion dollar deal with Novartis, the road is now well-paved for many others with gene, gene editing and genome editing platforms to move forward.  

While Kite and Juno, two companies with CAR T platforms, had huge acquisition numbers in 2018, cell therapy in 2019 will expand into other therapeutic applications with Bluerock Therapeutics a company that raised a record a round of $230 million building new medicines in Neurology, Cardiology and Autoimmunity.

It is not all about Oncology:

While therapeutics in oncology especially immune-oncology have been leading the investment cycle, we started to see expansion into neuroscience with what has been labeled the Neuroscience Renaissance. Companies like Annexon Biosciences, Denali Therapeutics, and Alector have raised huge sums of capital and are poised in 2019 to move forward building medicines for neurodegenerative diseases like Alzheimer’s Huntington’s and Parkinson’s.

It is a rare time to be in the biotech industry:

Despite the Administration’s plan to cut research dollars for biomedical research utilized by rare disease patients, rare disease biotech’s saw an increase in numbers and we also had some IPOs with Logic Biotherapeutics, Eidos, and Avrobio being a few going out this year.  We believe the trend will continue. The patient population is obviously in great need and the path to commercialization is also easier for young companies for a variety of reasons. 

We look forward to helping find and hire the talent needed for our clients to help them reach their goals bringing better medicines for patients.

 

Endotronix Raises $45 Million in Series D Financing for the Treatment of Heart Failure 

NEWS PROVIDED BY Endotronix, Inc.    Sep 14, 2018

LISLE, Ill., Sept. 14, 2018 /PRNewswire/ -- Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced the close of a Series D financing round totaling $45 million. The round was led by LSP, investing from its LSP Health Economics Fund 2, and included Aperture Venture PartnersBioVentures InvestorsLumira VenturesOSF VenturesSeroba Life SciencesSV Health InvestorsWanxiang Healthcare Investments, and an unnamed corporate strategic investor. Endotronix will expand the board of directors to include Fouad Azzam Ph.D., General Partner at LSP.

This financing supports the commercialization of the Cordella™ Heart Failure System (Cordella System) and clinical development of the Cordella™ Pulmonary Artery Sensor (Cordella Sensor) through CE Marking and FDA Premarket Approval (PMA). The product platform consists of a comprehensive remote patient management software solution coupled with a seamlessly integrated, next generation implantable pulmonary artery sensor to streamline heart failure care management and provide early detection of worsening heart failure.

"We are thrilled with the world-class leadership and support of LSP and our existing investor group as we launch into the next phase of our company," commented Harry Rowland, CEO of Endotronix. "This financing accelerates our U.S. and E.U. launch of the Cordella System and supports our upcoming landmark randomized, controlled clinical study, PROACTIVE-HF, to demonstrate the safety and effectiveness of proactive heart failure management."

The Cordella System is designed to address inefficiencies in heart failure management and promote guideline-based therapy so physicians can improve patient care and reduce re-hospitalizations with effective and scalable remote patient management. Over 26 million people worldwide suffer from heart failure and it is a leading cause of re-hospitalization for people over 651,2. With U.S. treatment costs reaching $31B per year, heart failure management remains a pressing unmet clinical need3

"Endotronix is on the cusp of transforming heart failure management," stated Fouad Azzam. "Their scalable Cordella System enables streamlined and timely flow of clinical-level information that can improve patient outcomes and supports sustainable care delivery revenue for healthcare providers.  We're excited to be part of the team to drive this transformation in the heart failure market." 

This announcement builds on the earlier news of successful first-in-human use of the Cordella Sensor in Europe and first commercial use of the Cordella System at select U.S. sites. 

About the Cordella™ Heart Failure System
The Cordella Heart Failure System is a proactive heart failure management solution that brings patient management into the digital age and allows physicians to treat more patients with guideline-based therapy. The easy-to-use system extends clinical care into the home by collecting and securely transmitting daily patient data and insights to the heart failure clinician to guide therapy and optimal dosing. In the U.S. market, the system drives care delivery revenue using Medicare's existing Chronic Care Management Services to support proactive, high-quality heart failure care. For suitable patients, the system seamlessly integrates pulmonary artery pressure data with a next generation wireless, implantable sensor. Clinical studies have demonstrated that pulmonary artery pressure-guided management can reduce heart failure-related hospitalizations and reduce mortality. 

About Endotronix, Inc.
Endotronix, Inc., a digital health, medtech company, is developing an integrated platform to provide comprehensive, reimbursable health management tools for patients suffering from chronic heart failure. The company's comprehensive solution includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable wireless pulmonary artery sensor for early detection of worsening heart failure.  Learn more at www.endotronix.com

About LSP
LSP (Life Sciences Partners) is an independent European investment firm, providing financing for private and public life sciences companies. LSP's mission is to connect investors to inventors, focusing on unmet medical needs. Since the late 1980s, the LSP team has invested in about 100 innovative enterprises, many of which have grown to become leaders of the global life sciences industry. With over €1.7 billion ($2.0 billion) of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is Europe's leading life sciences investor. The LSP Health Economics Fund 2 invests in innovative products that can increase the quality of health care, while reducing the cost of care. For more information, please visit: www.lspvc.com.

1 Ponikowski P et al. Heart failure: preventing disease and death worldwide. ESC Heart Failure 2015;1:4–25

2 Mozzafarian D, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016

3 Joo H, et al. Cost on Informal Caregiving for Patients with Heart Failure. Am Heart J. 2015 Jan;169(1):142–48.e2.

MEDIA CONTACT:
Carla Benigni
SPRIG Consulting LLC
(847) 951-7430
Carla@sprigconsulting.com

 

 

 

 

 

Fractyl presents One - Year Data on Revita DMR in Type II Diabetes

LEXINGTON, Mass., September 12, 2017 – Fractyl Laboratories Inc. (Fractyl) and clinical investigators for the Revita-1 clinical trial today report one-year data from the study showing sustained improvement in glycemic parameters following a single treatment with Revita™ DMR in patients with type 2 diabetes (T2D). The data will be presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal more

 

Sanderson McLeod hires VP of Manufacturing  for Turnstone Biologics

OTTAWA, Ontario & NEW YORK--()--Turnstone Biologics, a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies, today announced the recent appointment of Kris Elverum as chief business officer and José Manuel (Manny) Otero, Ph.D., as vice president, manufacturing and CMC (chemistry, manufacturing and controls). Mr. Elverum joins from SQZ Biotech, where he was chief business officer, and Dr. Otero joins from Seres Therapeutics, where he was vice president of bioprocess development and manufacturing. more

 

Sanderson McLeod hires Chief Scientific Officer for Heat Biologics

DURHAM, N.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced the appointment of Jeff Hutchins, Ph.D., as Chief Scientific Officer and Senior Vice President of Preclinical Development. Dr. Hutchins will be overseeing Heat’s research efforts, bringing over 24 years of research and clinical development experience from both large pharmaceutical and biotechnology companies more

Arch Therapeutics meets primary and secondary endpoints in first clinical study

FRAMINGHAM, MA -- (Marketwired) -- 08/15/16 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, successfully met the objectives of its recently completed single-center, randomized, single-blind prospective clinical study (NCT 02704104) of the AC5 Topical Hemostatic Device in skin lesion patients with bleeding wounds. This was the first study assessing the safety and performance of AC5 in human more

Fractyl reports postive data for intestinal resurfacing to treat diabetes

While multiple diabetes associations have recommended bariatric surgery as a standard treatment for some diabetics, it's still unsuitable for the mass treatment of patients. Enter Fractyl Labs, which just reported data from the first-in-human study of its endoscopic duodenal mucosal resurfacing treatment more

Flagship creates a CMO role for their venture firm

Flagship Ventures has created a new spot for former Merck EVP and CMO Dr. Michael Rosenblatt, benefiting from the R&D reorg at the pharma. He is joining the venture firm as CMO. Flagship is creating the position with Rosenblatt's hire. more

Gemphire goes public

August 4, 2016 - Gemphire Therapeutics managed to get its IPO out in the dog days of summer. But it languished several weeks and then had to cut its pricing expectations. The company expects to use the $30 million it has raised for late-stage testing of its gemcabene in a trio of dyslipidemia disorders. more

 

Medtronic buys Heartware in 1.1 billion dollar deal

Medical device maker Medtronic said Monday it would buy HeartWare International, a company best known for its HVAD heart pump designed to help with heart failure for $1.1 billion. The mechanical pump requires less invasive surgery than other treatments for heart failure.more

Gemphire Therapeutics sets IPO for Thursday 6-23-2016

Northville-based Gemphire Therapeutics Inc., a cardiovascular drug development company, is scheduled to have its initial public offering on the Nasdaq Stock Exchange on Thursday, according to a posting on the Nasdaq website Monday. more

 

From Fierce Drug Delivery

Engineered proteins direct drugs to difficult tumors  Researchers at Stanford have developed a targeted approach to cancer treatment using not the usual antibodies but engineered proteins to direct drugs to a tumor. The proteins boast several advantages over antibodies, which can be fairly limited in their approach--one such advantage could be their ability to cross the blood-brain barrier and treat cancers there. more

Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting LOS ANGELES, Calif., June 5, 2016

- Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, presented positive results from an investigator sponsored Phase II trial of neratinib with HER2-mutated, non-amplified breast cancer. The data were presented today in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, Illinois. The poster (Abstract #516), entitled "Phase II Trial of Neratinib for HER2 Mutated, Non-Amplified Metastatic Breast Cancer (HER2mutMBC), was presented from 8:00-11:30 a.m. CDT today with a poster presentation discussion occurring immediately following the poster session.  more

HeartWare Completes Enrollment In HVAD® System LATERAL Study

FRAMINGHAM, Mass., April 27, 2016 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced completion of enrollment in the HeartWare ® Ventricular Assist System (HVAD® System) LATERAL Study. more